BEDROSIAN v. THE UNITED STATES OF AMERICA, DEPARTMENT OF THE TREASURY, INTERNAL REVENUE SERVICE
Case Number:
2:15-cv-05853
Court:
Nature of Suit:
Judge:
Firms
-
June 21, 2021
Ex-Lannett CEO Gets $1.4M FBAR Judgment Paused For Appeal
A Pennsylvania federal court on Monday granted a motion to stay the $1.4 million judgment against a former CEO of the generic-drug maker Lannett for failing to report his foreign accounts while he appeals his case.
-
January 29, 2021
Ex-Lannett CEO Ruled To Owe $1.4M FBAR Penalty
The U.S. government is justified in imposing a maximum penalty of $1.4 million against the former chief executive officer of the generic drugmaker Lannett for failing to report his foreign bank accounts, a Pennsylvania federal court ruled Friday.
-
December 04, 2020
Drug Co. Ex-CEO Liable For $1M FBAR Penalty
A pharmaceutical company's former CEO faces a $1 million penalty for failing to disclose a foreign bank account after a federal court decided Friday he recklessly disregarded his duty to file.
-
April 29, 2019
Ex-Drug Co. CEO's Actions Merit $1M FBAR Penalty, US Says
A pharmaceutical company's former chief executive officer acted recklessly when he failed to disclose a foreign bank account worth $2 million, warranting a stiffer penalty of almost $1 million, the U.S. told a Pennsylvania federal court.
-
September 21, 2017
CEO's Oversight Doesn't Merit $1M Tax Penalty, Judge Says
A Pennsylvania federal judge on Wednesday sided with a pharmaceutical CEO challenging a nearly $1 million tax penalty, ruling after a bench trial that while the executive may have been negligent when he failed to disclose a Swiss bank account, he didn't willfully violate an IRS reporting requirement.
-
September 15, 2017
CEO's Unreported Bank Account Was No Accident, IRS Says
The IRS urged a Pennsylvania federal court Thursday to find that a pharmaceutical CEO acted willfully when he failed to disclose the existence of a decades-old Swiss bank account with $2 million in it, saying the facts presented at a recent bench trial leave nothing to the imagination.
-
September 05, 2017
IRS Can Keep Docs Out Of CEO's $1M Tax Penalty Trial
The CEO of generic-drug maker Lannett Co. cannot introduce IRS investigation documents at trial in his challenge of a nearly $1 million tax penalty, a Pennsylvania federal judge ruled on Tuesday, finding the documents are not relevant to the question of whether he willfully failed to disclose a Swiss bank account.
-
August 24, 2017
IRS Says Agent Depositions Irrelevant To CEO's Penalty Suit
The government pressed a Pennsylvania federal judge on Wednesday not to allow the CEO of generic-drug maker Lannett Co. to introduce IRS agent depositions at trial in his challenge of a nearly $1 million tax penalty stemming from his allegedly willful failure to disclose a Swiss bank account.
-
April 14, 2017
Judge Denies Quick Wins In Lannett CEO's Tax Penalty Suit
A Pennsylvania federal judge found that questions remain over whether the CEO of generic-pharmaceutical company Lannett Co. willfully failed to disclose a Swiss bank account to the IRS, denying on Thursday quick wins to both sides in the CEO's suit over an allegedly unwarranted tax penalty.